BIND Biosciences Appoints Chief Financial Officer
News Jul 18, 2012
BIND Biosciences has announced that Andrew J. Hirsch has joined the company as its Chief Financial Officer.
Mr. Hirsch brings nearly twenty years of financial leadership and strategic management experience.
“We are very pleased to welcome Andrew to the BIND team,” said Scott Minick, President and Chief Executive Officer of BIND Biosciences.
Minick continued, “Andrew has been an outstanding performer in the biotechnology industry, including major accomplishments with high-growth companies in financing, M&A transactions, strategic planning and investor relations, and his experience will add additional strength to our management team as our growth accelerates.”
“This is an exciting time to be joining BIND as BIND-014, the company’s lead Accurin drug candidate continues to show promise as an important medicine for solid tumors as it advances in the clinic and the company’s platform for developing highly selective targeted therapeutics is generating a pipeline of important medicines for patients.,” said Andrew Hirsch.
Prior to joining BIND, Mr. Hirsch was Chief Financial Officer at Avila Therapeutics until its acquisition by Celgene Inc. in March 2012.
Previously, Mr. Hirsch served in roles of increasing responsibility during his nearly ten year tenure at Biogen Idec, most recently as Vice President, Corporate Strategy and M&A, where he played a key role in developing a new strategy for the company and evaluating M&A opportunities.
Prior to that, Mr. Hirsch held various positions in the finance organization including leading the company’s Business Planning and Investor Relations functions.
Prior to joining Biogen Idec, Mr. Hirsch led business development for a software start-up company and spent several years in management consulting at both Stern Stewart & Co. and The Parthenon Group.
He holds a Masters of Business Administration from the Tuck School at Dartmouth College and a Bachelor of Arts in Economics from the University of Pennsylvania.
Combining Different Malaria Vaccines Could Reduce Cases by 91%News
Using two experimental anti-malarial vaccines, which work in different ways, can greatly reduce the number of malaria infections in animal studies. Experimental vaccines, which independently achieve 48% and 68% reductions in malaria cases, can achieve 91% reduction when combined.
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE